Biohaven Return on Equity

Biohaven (BHVN) currently reports a ROE of -4440.17%. That is below the Healthcare sector average of -75.84%. Use the charts on this page to explore Biohaven's ROE history and peer comparisons.

Biohaven's ROE of -4440.17% is lower than the Healthcare sector average of -75.84%. That is roughly 5755.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Biohaven's current -4440.17% should be judged against Healthcare norms (sector average: -75.84%) and against BHVN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -4440.17%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Biohaven, and consider following BHVN for alerts when major investors trade the stock.

Biohaven is classified in the Healthcare sector. On ROE, it currently shows -4440.17% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BHVN with unrelated industries.